Claims

1. A compound having the formula



(I)

the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

n represents an integer being 0, 1 or 2;

m represents an integer being 0 or 1;

R^1 and R^2 each independently represents hydrogen, C_{1-4}alkyl, NR^9R^{10}, C_{1-4}alkyloxy, Het^3-O-C_{1-4}alkyl; or

R^1 and R^2 taken together with the carbon atom with which they are attached form a carbonyl, or a C_{3-6}cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;

R^3 represents hydrogen, Ar^1, C_{1-8}alkyl, C_{6-12}cycloalkyl or a monovalent radical having one of the following formulae



wherein said Ar^1, C_{6-12}cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two or three substituents selected from the

group consisting of C_{1-4}alkyl, C_{1-4}alkyloxy, phenyl, halo, oxo, carbonyl, 1,3-dioxolyl or hydroxy;

R^4 represents hydrogen, C_{1-4}alkyl, or C_{2-4}alkenyl;

Q represents C_{3-8}cycloalkyl, Het^1 or Ar^2, wherein said C_{3-8}cycloalkyl, Het^1 or Ar^2 are optionally substituted with one or where possible more substituents selected from halo, C_{1-4}alkyl, C_{1-4}alkyloxy, hydroxy, nitro, Het^4, phenyl, phenyloxy, C_{1-4}alkyl-oxycarbonyl, hydroxycarbonyl, NR^5R^6, C_{1-4}alkyloxy substituted with one or where possible two or three substituents each independently selected from C_{1-4}alkyl, hydroxycarbonyl, Het^2, C_{1-4}alkyl or NR^7R^8,

C_{2-4}alkenyl substituted with one substituent selected from phenyl-C_{1-4}alkyl-oxycarbonyl, C_{1-4}alkyloxycarbonyl, hydroxycarbonyl or Het^5-carbonyl, and C_{1-4}alkyl substituted with one or where possible two or three substituents independently selected from halo, dimethylamine, trimethylamine, amine, cyano, Het^6, Het^7-carbonyl, C_{1-4}alkyloxycarbonyl or hydroxycarbonyl;

R^5 and R^6 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxy-C_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo, C_{1-4}alkyl, and C_{1-4}alkyloxy or R^5 and R^6 each independently represent C_{1-4}alkyl substituted with phenyl;

R^7 and R^8 are each independently selected from hydrogen or C_{1-4}alkyl;

R^9 and R^{10} are each independently selected from hydrogen, C_{1-4}alkyl or C_{1-4}alkyl-oxycarbonyl;

L represents C_{1-4}alkyl optionally substituted with one or where possible more substituents selected from C_{1-4}alkyl or phenyl;

Het^1 represents a heterocycle selected from pyridinyl, piperinidyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothiophenyl, thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

Het^2 represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl, said Het^2 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, C_{1-4}alkyl or C_{1-4}alkyloxy;

Het^3 represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;

Het^4 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl, triazolyl, tetrazolyl or morpholinyl, said Het^4 optionally being substituted with one or where possible two or more substituents each idependently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy;

Het^5 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^5 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy; in particular piperazinyl or morpholinyl;

Het^6 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^6 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy;

Het^7 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^7 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy; in particular selected piperazinyl or morpholinyl;

Ar^1 represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 5,6,7,8-tetrahydronaphtyl or naphthyl

Ar^2 represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, benzocyclobutenyl, benzocycloheptanyl, benzosuberenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 1,2-dihydronaphthyl, 5,6,7,8-tetrahydronaphthyl or naphthyl.

2. A compound having the formula



(I)

the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

n represents an integer being 0, 1 or 2;

m represents an integer being 0 or 1;

R^1 and R^2 each independently represents hydrogen, C_{1-4}alkyl, NR^9R^{10}, C_{1-4}alkyloxy, Het^3-O-C_{1-4}alkyl; or

R^1 and R^2 taken together with the carbon atom with which they are attached form a carbonyl, or a C_{3-6}cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;

R^3 represents hydrogen, Ar^1, C_{1-8}alkyl, C_{6-12}cycloalkyl or a monovalent radical having one of the following formulae



wherein said Ar^1, C_{6-12}cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two or three substituents selected from the group consisting of C_{1-4}alkyl, C_{1-4}alkyloxy, phenyl, halo, oxo, carbonyl, 1,3-dioxolyl or hydroxy;

R^4 represents hydrogen or C_{1-4}alkyl;

Q represents C_{3-8}cycloalkyl, Het^1 or Ar^2, wherein said C_{3-8}cycloalkyl, Het^1 or Ar^2 are optionally substituted with one or where possible more substituents selected from halo, C_{1-4}alkyl, C_{1-4}alkyloxy, hydroxy, nitro, Het^4, phenyl, phenyloxy, C_{1-4}alkyloxycarbonyl, hydroxycarbonyl, NR^5R^6, C_{1-4}alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8, and

C_{1-4}alkyl substituted with one or where possible two or three halo substituents;

R^5 and R^6 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl substituted with

one or where possible two or three substituents each independently selected from halo, C_{1-4}alkyl, and C_{1-4}alkyloxy or R^5 and R^6 each independently represent C_{1-4}alkyl substituted with phenyl;

R^7 and R^8 are each independently selected from hydrogen or C_{1-4}alkyl;

R^9 and R^{10} are each independently selected from hydrogen, C_{1-4}alkyl or C_{1-4}alkyloxycarbonyl;

L represents C_{1-4}alkyl optionally substituted with one or where possible more substituents selected from C_{1-4}alkyl or phenyl;

Het^1 represents a heterocycle selected from pyridinyl, piperinidyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothiophenyl, thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, or 1,3-benzodioxolyl.;

Het^2 represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl;

Het^3 represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;

Het^4 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^4 optionally being substituted with one or where possible two or more substituents each idependently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy;

Ar^1 represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 5,6,7,8-tetrahydronaphtyl or naphtyl

Ar^2 represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, biphenyl, indenyl, 2,3-dihydroindenyl, fluorenyl, 5,6,7,8-tetrahydronaphtyl or naphtyl.

3. A compound according to claims 1 or 2 wherein;

n represents an integer being 1 or 2 provided that when n represents 2, Q represents Het^1 or Ar^2, wherein said Het^1 or Ar^2 are optionally substituted with one or where possible more substituents selected from halo, C_{1-4}alkyl, C_{1-4}alkyloxy, hydroxy, nitro, Het^4, phenyl, phenyloxy, hydroxycarbonyl, NR^5R^6, C_{1-4}alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8, and

C_{1-4}alkyl substituted with one or where possible two or three halo substituents

4. A compound according to any one of claims 1 to 3 wherein;

R^1 and R^2 each independently represents hydrogen C_{1-4}alkyl, NR^9R^{10}; or R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6}cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;

R^3 represents a C_{6-12}cycloalkyl or a monovalent radical having one of the following formulae



wherein said C_{6-12}cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4}alkyl, C_{1-4}alkyloxy, halo, carbonyl, hydroxy, or 1,3-dioxolyl;

Q represents Het^1 or Ar^2 wherein said Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4}alkyl, C_{1-4}alkyloxy, hydroxy, C_{1-4}alkyloxycarbonyl, NR^5R^6, C_{1-4}alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8, and C_{1-4}alkyl substituted with one or where possible two or three substituents each independently selected from halo, dimethylamine, amine, cyano, Het^6, Het^7-carbonyl or hydroxycarbonyl;

R^5 and R^6 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl substituted with one or where possible two or three halo substituents.

R^9 and R^{10} are each independently selected from hydrogen or C_{1-4}alkyl;

L represents a C_{1-4}alkyl, preferably methyl;

Het^1 represents a heterocycle selected from pyridinyl, pyrimidinyl, thiophenyl, benzothiophenyl, quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

Het^2 represents a monocyclic heterocycle selected from piperidinyl, piperazinyl, pyridinyl, pyrrolidinyl or morpholinyl, said Het^2 optionally being substituted with one or where possible two or more C_{1-4}alkyl substituents ;

Het^4 represents tetrazolyl;

Het^5 represents morpholinyl;

Het^6 represents a monocyclic heterocycle selected from pyrrolidinyl, piperazinyl or morpholinyl, said Het^6 optionally being substituted with one or where possible two or more hydroxy substituents, preferably with one hydroxy substituent;

Ar^2 represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, benzocyclobutene, benzocycloheptanyl, benzosuberenyl, indenyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl.

5. A compound according to any one of claims 1 to 3 wherein;

R^1 and R^2 each independently represents hydrogen C_{1-4}alkyl, NR^9R^{10}; or

R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6}cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;

R^3represents a C_{6-12}cycloalkyl or a monovalent radical having one of the following formulae



wherein said C_{6-12}cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4}alkyl, C_{1-4}alkyloxy, halo, carbonyl, hydroxy, or 1,3-dioxolyl;

Q represents Het^1 or Ar^2 wherein said Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4}alkyl, C_{1-4}alkyloxy, hydroxy, C_{1-4}alkyloxycarbonyl, Het^4, NR^5R^6, C_{1-4}alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8,

C_{2-4}alkenyl substituted with one substituent selected from phenyl-C_{1-4}alkyl-oxycarbonyl or Het^5-carbonyl and

C_{1-4}alkyl substituted with one or where possible two or three substituents each independently selected from halo, dimethylamine, amine, cyano, Het^6, Het^7-carbonyl or hydroxycarbonyl;

R^5 and R^6 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl substituted with one or where possible two or three halo substituents.

R^9 and R^{10} are each independently selected from hydrogen or C_{1-4}alkyl;

L represents a C_{1-4}alkyl, preferably methyl;

Het^1 represents a heterocycle selected from pyridinyl, pyrimidinyl, indolyl, thiophenyl, benzothiophenyl, quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

Het^2 represents a monocyclic heterocycle selected from piperidinyl, piperazinyl, pyridinyl, pyrrolidinyl or morpholinyl, said Het^2 optionally being substituted with one or where possible two or more C_{1-4}alkyl substituents ;

Het^4 represents tetrazolyl;

Het^5 represents morpholinyl;

Het^6 represents a monocyclic heterocycle selected from pyrrolidinyl, piperazinyl or morpholinyl, said Het^6 optionally being substituted with one or where possible two or more hydroxy substituents, preferably with one hydroxy substituent;

Het^7 represents a monocyclic heterocycle selected from piperazinyl or morpholinyl, preferably morpholinyl;

Ar^2 represents carbocyclic radicals containing one or more rings selected from the group consisting of phenyl, benzocyclobutene, benzocycloheptanyl, benzosuberenyl, indenyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphthyl or naphthyl.

6. A compound according to any one of claims 1 to 3 wherein;

n represents an integer being 0, 1 or 2;

R^1 and R^2 each independently represents hydrogen, C_{1-4}alkyl, NR^9R^{10}; or R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6}cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;

R^3 represents a C_{6-12}cycloalkyl, preferably cylo-octanyl or a monovalent radical having one of the following formulae



, preferably having the formula (a) or (b) above, wherein said C_{6-12}cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4}alkyl, C_{1-4}alkyloxy, halo or hydroxy;

Q represents Het^1 or Ar^2 wherein said Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4}alkyl, C_{1-4}alkyloxy, hydroxy, NR^5R^6, C_{1-4}alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het^2 or NR^7R^8, C_{2-4}alkenyl substituted with one substituent selected from phenyl-C_{1-4}alkyl-oxycarbonyl or Het^5-carbonyl

and C_{1-4}alkyl substituted with one or where possible two or three substituents selected from halo, Het^6, C_{1-4}alkyloxycarbonyl or hydroxycarbonyl;

R^5 and R^6 each independently represent hydrogen or C_{1-4}alkyl;

R^9 and R^{10} each independently represent hydrogen or C_{1-4}alkyloxycarbonyl;

L represents C_{1-4}alkyl;

Het^1 represents a heterocycle selected from pyridinyl, piperidinyl, thiophenyl, 1,2,3,4-tetrahydro-quinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxol;

Het^2 represents pyridinyl, pyrrolidinyl or morpholinyl;

Het^6 represents morpholinyl;

Ar^2 represents phenyl, benzocyclobutene, benzocycloheptanyl, benzosuberenyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphthyl, naphtyl or indenyl.

7. A compound as claimed in claim 1 wherein

n represents an integer being 0, 1 or 2;

(R^1 and R^2 each independently represents hydrogen C_{1-4}alkyl, NR^9R^{10}, C_{1-4}alkyloxy; or

R^1 and R^2 taken together with the carbon atom with which they are attached form a C_{3-6}cycloalkyl; and where n is 2, either R^1 or R^2 may be absent to form an unsaturated bond;

R^3 represents a C_{6-12}cycloalkyl, preferably selected from cylo-octanyl and cyclohexyl or R^3 represents a monovalent radical having one of the following formulae



, preferably having the formula (a) above, wherein said C_{6-12}cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C_{1-4}alkyl, C_{1-4}alkyloxy, halo or hydroxy;

R^4 represents hydrogen or C_{1-4}alkyl;

Q represents Het^1 or Ar^2 wherein said C_{3-8}cycloalkyl, Het^1 or Ar^2 are optionally substituted with one or where possible two or more substituents selected from halo, C_{1-4}alkyl, C_{1-4}alkyloxy, hydroxy, nitro, NR^5R^6, C_{1-4}alkyloxy substituted with one or where possible two, three or more substituents each independently selected from hydroxycarbonyl, Het^2 or NR^7R^8, C_{2-4}alkenyl substituted with phenyl-C_{1-4}alkyl-oxycarbonyl and C_{1-4}alkyl substituted with one or where possible two or three substituents selected from, halo, Het^6, Het^7-carbonyl, C_{1-4}alkyloxycarbonyl or hydroxycarbonyl;

R^5 and R^6 each independently represent hydrogen, C_{1-4}alkyl, or C_{1-4}alkyl substituted with phenyl;

L represents C_{1-4}alkyl;

Het^1 represents a heterocycle selected from pyridinyl, thiophenyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

Het^2 represents piperidinyl, pyrrolidinyl or morpholinyl;

Het^6 represents a monocyclic heterocycle selected from piperazinyl or morpholinyl, preferably morpholinyl;

Ar^2 represents phenyl, benzocyclobutene, benzocycloheptanyl, benzosuberenyl, 2,3-dihydroindenyl, 1,2-dihydronaphthyl, 5,6,7,8-tetrahydronaphthyl, naphtyl or indenyl.

8. A compound as claimed in claim 1 wherein the compound is
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-methyl-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-methoxy-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-hydroxy-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3,5-dimethyl-benzeneacetamide);
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-3-(phenylmethoxy)benzeneacetamide;

(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-(carboxymethoxy)-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-[2-(4-morpholinyl)ethoxy]-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-fluorotricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-benzeneacetamide;
(1α,2α,3β,5β,7β)-N-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-(carboxymethoxy)-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-[2-(4-morpholinyl)ethoxy]-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3,5-dimethoxy-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-methyl-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-methoxy-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-hydroxy-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3,5-dimethyl-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-4-fluoro-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-1-phenyl-cyclopropanecarboxamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-2,6-difluoro-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-2-thiopheneacetamide;
N-(5-hydroxy-2-adamantyl)-2-methyl-2-(5-methylpyridin-3-yl)propanamide;
N-(5-hydroxy-2-adamantyl)-2-methyl-2-(6-methylpyridin-2-yl)propanamide;
3-(3-{2-[(5-fluoro-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoic acid;
4-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)butanoic acid;
tert-butyl-4-[3-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoyl]-1,4-diazepane-1-carboxylate;
N-(5-hydroxy-2-adamantyl)-5-methoxy-1,2,3,4-tetrahydronaphthalene-1-carboxamide;
N-2-adamantyl-1,2,3,4-tetrahydroisoquinoline-1-carboxamide;

N-(5-hydroxy-2-adamantyl)-3,4-dihydroquinoline-1(2*H*)-carboxamide; or a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, an effective 11β-HSD1 inhibitory amount of a compound as described in any one of claims 1 to 8.

10. A process of preparing a pharmaceutical composition as defined in claim 8, characterized in that, a pharmaceutically acceptable carrier is intimately mixed with an effective 11β-HSD1 inhibitory amount of a compound as described in any one of claims 1 to 8.

11. A compound as claimed in any one of claims 1 to 8 for use as a medicine.

12. Use of a compound as claimed in any one of claims 1 to 8 in the manufacture of a medicament for treating pathologies associated with excess cortisol formation such as for example, obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis and glaucoma.

13. A compound of formula (I')



(I')

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof wherein

R^1 and R^2 each independently represents hydrogen, C_{1-4}alkyl, NR^9R^{10}, C_{1-4}alkyloxy or Het^3-O-C_{1-4}alkyl; preferably C_{1-4}alkyl in particular methyl; or
R^1 and R^2 taken together with the carbon atom with which they are attached from a C_{3-6}cycloalkyl, in particular cyclopropyl or cyclobutyl;
R^4 represents hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl;
U represents hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxy, phenyl, halo, oxo, carbonyl or hydroxy
R^5 and R^6 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl substituted with

one or where possible two or three substituents each independently selected from halo, C_{1-4}alkyl, and C_{1-4}alkyloxy or R^5 and R^6 each independently represent C_{1-4}alkyl substituted with phenyl;

R^7 and R^8 are each independently selected from hydrogen or C_{1-4}alkyl;

R^9 and R^{10} are each independently selected from hydrogen, C_{1-4}alkyl or C_{1-4}alkyloxycarbonyl;

R^{11} and R^{12} are each independently selected from hydrogen, halo, C_{1-4}alkyl, C_{1-4}alkyloxy, hydroxy, nitro, Het^4, phenyl, phenyloxy, C_{1-4}alkyloxycarbonyl, hydroxycarbonyl, NR^5R^6, C_{1-4}alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8, C_{2-4}alkenyl substituted with one substituent selected from phenyl-C_{1-4}alkyl-oxycarbonyl, C_{1-4}alkyloxycarbonyl, hydroxycarbonyl, Het^5-carbonyl, and C_{1-4}alkyl substituted with one or where possible two or three substituents independently selected from halo, dimethylamine, trimethylamine, amine, cyano, Het^6, Het^7-carbonyl, C_{1-4}alkyloxycarbonyl or hydroxycarbonyl;

Het^1 represents a heterocycle selected from pyridinyl, piperinidyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothiophenyl, thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl.;

Het^2 represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl, said Het^2 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy;;

Het^3 represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;

Het^4 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl, triazolyl, tetrazolyl or morpholinyl, said Het^4 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy;

Het^5 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^5 optionally being substituted with one or where possible two or more substituents each

independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy; preferably piperazinyl or morpholinyl;

Het^6 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^6 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy;

Het^7 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^7 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy; preferably piperazinyl or morpholinyl; in particular morpholinyl.

14. A compound of formula (I'')



(I'')

the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

R^4 represents hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl;

U represents hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxy, phenyl, halo, oxo, carbonyl or hydroxy

Q represents Het^1 or Ar^2, wherein said Het^1 or Ar^2 are optionally substituted with one or where possible more substituents selected from halo, C_{1-4}alkyl, C_{1-4}alkyloxy, hydroxy, nitro, Het^4, phenyl, phenyloxy, C_{1-4}alkyloxycarbonyl, hydroxycarbonyl, NR^5R^6,

C_{1-4}alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8, and

C_{1-4}alkyl substituted with one or where possible two or three substituents independently selected from halo or hydroxycarbonyl;

R^5 and R^6 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo, C_{1-4}alkyl, and C_{1-4}alkyloxy or R^5 and R^6 each independently represent C_{1-4}alkyl substituted with phenyl;

R^7 and R^8 are each independently selected from hydrogen or C_{1-4}alkyl;

R^9 and R^{10} are each independently selected from hydrogen, C_{1-4}alkyl or C_{1-4}alkyloxycarbonyl;

Het^1 represents a bicyclic heterocycle selected from indolyl, isoindolyl, indolinyl, benzofuranyl, benzothiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, 1,2,3,4-tetrahydro-quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl.;

Het^2 represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl, said Het^2 optionally being

substituted with one or where possible two or more substituents each independently selected from hydroxy, C_{1-4}alkyl or C_{1-4}alkyloxy;

Het^3 represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;

Het^4 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^4 optionally being substituted with one or where possible two or more substituents each idependently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy;

Ar^2 represents carbocyclic radicals containing two rings selected from the group consisting of benzocyclobutene, benzocycloheptanyl, benzosurbenyl, indenyl, 2,3-dihydroindenyl, 5,6,7,8-tetrahydronaphtyl or naphthyl.

15. A compound of formula (I') or (I'') for use as a medicine.

16. Use of a compound of formula (I') or (I'') in the manufacture of a medicament for treating pathologies associated with excess cortisol formation such as for example, obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis and glaucoma.

17. A method to prepare 1-hydroxy-4-aminoadamantane said method comprising
    i) the reductive amination of the corresponding ketone (XIII);
    ii) separating the thus obtained stereomers of the amine of formula (XVIII); and
    iii) debenzylating the compounds of formula (XVIII)